KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.19
−1.50%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.96
- Revenue estimate
- $14.8M
Latest reported
- Last report date
- Aug 3, 2026
- EPS actual
- -$1.45
- EPS estimate
- -$1.34
- Revenue actual
- —
- Revenue estimate
- $807.1K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -7.9%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $21
- PT range
- $18 – $23
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 3, 2026 | -$1.34 | -$1.45 | Miss -8.21% | — |
| May 14, 2026 | -$0.92 | -$1.21 | Miss -31.52% | $367.0K |
| Mar 4, 2026 | -$0.49 | -$0.86 | Miss -75.51% | $385.0K |
| Nov 5, 2025 | -$1.11 | -$0.18 | Beat 83.78% | $14.3M |
| Aug 6, 2025 | -$1.14 | -$0.76 | Beat 33.33% | $18.2M |
| Feb 26, 2025 | -$1.36 | -$1.14 | Beat 16.18% | $3.0M |
| Feb 28, 2024 | -$1.38 | -$1.34 | Beat 2.90% | $143.0K |
| May 4, 2023 | -$1.13 | -$1.26 | Miss -11.50% | — |
| Mar 3, 2023 | -$1.12 | -$1.09 | Beat 2.68% | — |
| Nov 3, 2022 | -$1.26 | -$0.92 | Beat 26.98% | — |
| Aug 4, 2022 | -$1.07 | -$1.13 | Miss -5.61% | $100.0K |
| May 5, 2022 | -$0.86 | -$1.01 | Miss -17.44% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026